Search results 16,540
Showing results 1 to 10
-
Vaccination
https://health.ec.europa.eu/vaccination_enVaccination
-
Vaccination
https://health.ec.europa.eu/vaccination_enVaccination
-
communication-eu-strategy-vaccines-covid19_fr.pdf
https://commission.europa.eu/document/download/3e780eef-7...FR FR COMMISSION EUROPÉENNE Bruxelles, le 17.6.2020 COM(2020) 245 final COMMUNICATION DE LA COMMISSION AU PARLEMENT EUROPÉEN, AU CONSEIL EUROPÉEN, AU CONSEIL ET À LA BANQUE EUROPÉENNE D'INVESTISSEMENT Stratégie de l’Union européenne concernant les vaccins contre la COVID-19 1 1. IL EST URGENT D’AGIR La pandémie de COVID-19 a un coût
-
mobile vaccination caravan and COVID-19 vaccine uptake
https://publications.jrc.ec.europa.eu/repository/handle/J...Over three years since the first COVID-19 vaccine was approved, many countries still have suboptimal vaccination rates despite holding great amounts of vaccines. Overall, there is little evidence on which policies are more effective to encourage vaccination, particularly in countries where a large share of the population remains unvaccinated
-
EU Vaccines Strategy
https://commission.europa.eu/strategy-and-policy/coronavi...The development and deployment of an effective and safe vaccine against the coronavirus represents a permanent solution to the pandemic.
-
Bluetongue conference on vaccination
https://food.ec.europa.eu/animals/animal-diseases/surveil...Conference held in Brussels - 16 January 2008
-
Vaccine-preventable cancers
https://health.ec.europa.eu/vaccination/vaccine-preventab...Cancers caused by Human papillomaviruses (HPV) and Hepatitis B virus (HBV) can be prevented thanks to vaccination.
-
A groundbreaking coronavirus vaccine
https://research-and-innovation.ec.europa.eu/events/speci...Right after the pandemic started, the EU rapidly implemented several measures to respond to COVID-19. One notable action was providing funding and a guarantee through the European Investment Bank (EIB) to help BioNTech in developing a safe and effective vaccine.
-
Improving vaccines
https://publications.jrc.ec.europa.eu/repository/handle/J...Adjuvants have been used for decades to enhance the immune response to vaccines, in particular for the subunit-based ones. Physicochemical properties of the adjuvant-protein antigen complexes, such as size, morphology, protein structure and binding, influence the overall efficacy and safety of the vaccine. Here we show how to perform an accurate
-
Behavioural insights applied to vaccination
https://publications.jrc.ec.europa.eu/repository/handle/J...This JRC technical report gives an overview of a large project on vaccination acceptance and demand and illustrates its outcomes and lessons learnt. The project started at the end of 2019 and was completed in 2022. The overarching objective of the project was to facilitate and execute research on vaccine confidence, identifying behavioural
-
Optimal vaccination strategies
https://publications.jrc.ec.europa.eu/repository/handle/J...Optimal distribution of vaccines to achieve high population immunity levels is a desirable aim in infectious disease epidemiology. A distributed optimal control epidemiological model that accounts for vaccination was developed and applied to the case of the COVID-19 pandemic. The model proposed here is nonstandard and takes into account
-
-
communication-eu-strategy-vaccines-covid19_fr.pdf
https://commission.europa.eu/document/download/3e780eef-7...FR FR COMMISSION EUROPÉENNE Bruxelles, le 17.6.2020 COM(2020) 245 final COMMUNICATION DE LA COMMISSION AU PARLEMENT EUROPÉEN, AU CONSEIL EUROPÉEN, AU CONSEIL ET À LA BANQUE EUROPÉENNE D'INVESTISSEMENT Stratégie de l’Union européenne concernant les vaccins contre la COVID-19 1 1. IL EST URGENT D’AGIR La pandémie de COVID-19 a un coût
-
Vaccination
https://health.ec.europa.eu/vaccination_enVaccination
-
communication-eu-strategy-vaccines-covid19_fr.pdf
https://commission.europa.eu/document/download/3e780eef-7...FR FR COMMISSION EUROPÉENNE Bruxelles, le 17.6.2020 COM(2020) 245 final COMMUNICATION DE LA COMMISSION AU PARLEMENT EUROPÉEN, AU CONSEIL EUROPÉEN, AU CONSEIL ET À LA BANQUE EUROPÉENNE D'INVESTISSEMENT Stratégie de l’Union européenne concernant les vaccins contre la COVID-19 1 1. IL EST URGENT D’AGIR La pandémie de COVID-19 a un coût
-
mobile vaccination caravan and COVID-19 vaccine uptake
https://publications.jrc.ec.europa.eu/repository/handle/J...Over three years since the first COVID-19 vaccine was approved, many countries still have suboptimal vaccination rates despite holding great amounts of vaccines. Overall, there is little evidence on which policies are more effective to encourage vaccination, particularly in countries where a large share of the population remains unvaccinated
-
EU Vaccines Strategy
https://commission.europa.eu/strategy-and-policy/coronavi...The development and deployment of an effective and safe vaccine against the coronavirus represents a permanent solution to the pandemic.
-
Bluetongue conference on vaccination
https://food.ec.europa.eu/animals/animal-diseases/surveil...Conference held in Brussels - 16 January 2008
-
Vaccine-preventable cancers
https://health.ec.europa.eu/vaccination/vaccine-preventab...Cancers caused by Human papillomaviruses (HPV) and Hepatitis B virus (HBV) can be prevented thanks to vaccination.
-
A groundbreaking coronavirus vaccine
https://research-and-innovation.ec.europa.eu/events/speci...Right after the pandemic started, the EU rapidly implemented several measures to respond to COVID-19. One notable action was providing funding and a guarantee through the European Investment Bank (EIB) to help BioNTech in developing a safe and effective vaccine.
-
Improving vaccines
https://publications.jrc.ec.europa.eu/repository/handle/J...Adjuvants have been used for decades to enhance the immune response to vaccines, in particular for the subunit-based ones. Physicochemical properties of the adjuvant-protein antigen complexes, such as size, morphology, protein structure and binding, influence the overall efficacy and safety of the vaccine. Here we show how to perform an accurate
-
Behavioural insights applied to vaccination
https://publications.jrc.ec.europa.eu/repository/handle/J...This JRC technical report gives an overview of a large project on vaccination acceptance and demand and illustrates its outcomes and lessons learnt. The project started at the end of 2019 and was completed in 2022. The overarching objective of the project was to facilitate and execute research on vaccine confidence, identifying behavioural
-
Optimal vaccination strategies
https://publications.jrc.ec.europa.eu/repository/handle/J...Optimal distribution of vaccines to achieve high population immunity levels is a desirable aim in infectious disease epidemiology. A distributed optimal control epidemiological model that accounts for vaccination was developed and applied to the case of the COVID-19 pandemic. The model proposed here is nonstandard and takes into account
-
-
mobile vaccination caravan and COVID-19 vaccine uptake
https://publications.jrc.ec.europa.eu/repository/handle/J...Over three years since the first COVID-19 vaccine was approved, many countries still have suboptimal vaccination rates despite holding great amounts of vaccines. Overall, there is little evidence on which policies are more effective to encourage vaccination, particularly in countries where a large share of the population remains unvaccinated
-
Vaccination
https://health.ec.europa.eu/vaccination_enVaccination
-
communication-eu-strategy-vaccines-covid19_fr.pdf
https://commission.europa.eu/document/download/3e780eef-7...FR FR COMMISSION EUROPÉENNE Bruxelles, le 17.6.2020 COM(2020) 245 final COMMUNICATION DE LA COMMISSION AU PARLEMENT EUROPÉEN, AU CONSEIL EUROPÉEN, AU CONSEIL ET À LA BANQUE EUROPÉENNE D'INVESTISSEMENT Stratégie de l’Union européenne concernant les vaccins contre la COVID-19 1 1. IL EST URGENT D’AGIR La pandémie de COVID-19 a un coût
-
mobile vaccination caravan and COVID-19 vaccine uptake
https://publications.jrc.ec.europa.eu/repository/handle/J...Over three years since the first COVID-19 vaccine was approved, many countries still have suboptimal vaccination rates despite holding great amounts of vaccines. Overall, there is little evidence on which policies are more effective to encourage vaccination, particularly in countries where a large share of the population remains unvaccinated
-
EU Vaccines Strategy
https://commission.europa.eu/strategy-and-policy/coronavi...The development and deployment of an effective and safe vaccine against the coronavirus represents a permanent solution to the pandemic.
-
Bluetongue conference on vaccination
https://food.ec.europa.eu/animals/animal-diseases/surveil...Conference held in Brussels - 16 January 2008
-
Vaccine-preventable cancers
https://health.ec.europa.eu/vaccination/vaccine-preventab...Cancers caused by Human papillomaviruses (HPV) and Hepatitis B virus (HBV) can be prevented thanks to vaccination.
-
A groundbreaking coronavirus vaccine
https://research-and-innovation.ec.europa.eu/events/speci...Right after the pandemic started, the EU rapidly implemented several measures to respond to COVID-19. One notable action was providing funding and a guarantee through the European Investment Bank (EIB) to help BioNTech in developing a safe and effective vaccine.
-
Improving vaccines
https://publications.jrc.ec.europa.eu/repository/handle/J...Adjuvants have been used for decades to enhance the immune response to vaccines, in particular for the subunit-based ones. Physicochemical properties of the adjuvant-protein antigen complexes, such as size, morphology, protein structure and binding, influence the overall efficacy and safety of the vaccine. Here we show how to perform an accurate
-
Behavioural insights applied to vaccination
https://publications.jrc.ec.europa.eu/repository/handle/J...This JRC technical report gives an overview of a large project on vaccination acceptance and demand and illustrates its outcomes and lessons learnt. The project started at the end of 2019 and was completed in 2022. The overarching objective of the project was to facilitate and execute research on vaccine confidence, identifying behavioural
-
Optimal vaccination strategies
https://publications.jrc.ec.europa.eu/repository/handle/J...Optimal distribution of vaccines to achieve high population immunity levels is a desirable aim in infectious disease epidemiology. A distributed optimal control epidemiological model that accounts for vaccination was developed and applied to the case of the COVID-19 pandemic. The model proposed here is nonstandard and takes into account
-
-
EU Vaccines Strategy
https://commission.europa.eu/strategy-and-policy/coronavi...The development and deployment of an effective and safe vaccine against the coronavirus represents a permanent solution to the pandemic.
-
Vaccination
https://health.ec.europa.eu/vaccination_enVaccination
-
communication-eu-strategy-vaccines-covid19_fr.pdf
https://commission.europa.eu/document/download/3e780eef-7...FR FR COMMISSION EUROPÉENNE Bruxelles, le 17.6.2020 COM(2020) 245 final COMMUNICATION DE LA COMMISSION AU PARLEMENT EUROPÉEN, AU CONSEIL EUROPÉEN, AU CONSEIL ET À LA BANQUE EUROPÉENNE D'INVESTISSEMENT Stratégie de l’Union européenne concernant les vaccins contre la COVID-19 1 1. IL EST URGENT D’AGIR La pandémie de COVID-19 a un coût
-
mobile vaccination caravan and COVID-19 vaccine uptake
https://publications.jrc.ec.europa.eu/repository/handle/J...Over three years since the first COVID-19 vaccine was approved, many countries still have suboptimal vaccination rates despite holding great amounts of vaccines. Overall, there is little evidence on which policies are more effective to encourage vaccination, particularly in countries where a large share of the population remains unvaccinated
-
EU Vaccines Strategy
https://commission.europa.eu/strategy-and-policy/coronavi...The development and deployment of an effective and safe vaccine against the coronavirus represents a permanent solution to the pandemic.
-
Bluetongue conference on vaccination
https://food.ec.europa.eu/animals/animal-diseases/surveil...Conference held in Brussels - 16 January 2008
-
Vaccine-preventable cancers
https://health.ec.europa.eu/vaccination/vaccine-preventab...Cancers caused by Human papillomaviruses (HPV) and Hepatitis B virus (HBV) can be prevented thanks to vaccination.
-
A groundbreaking coronavirus vaccine
https://research-and-innovation.ec.europa.eu/events/speci...Right after the pandemic started, the EU rapidly implemented several measures to respond to COVID-19. One notable action was providing funding and a guarantee through the European Investment Bank (EIB) to help BioNTech in developing a safe and effective vaccine.
-
Improving vaccines
https://publications.jrc.ec.europa.eu/repository/handle/J...Adjuvants have been used for decades to enhance the immune response to vaccines, in particular for the subunit-based ones. Physicochemical properties of the adjuvant-protein antigen complexes, such as size, morphology, protein structure and binding, influence the overall efficacy and safety of the vaccine. Here we show how to perform an accurate
-
Behavioural insights applied to vaccination
https://publications.jrc.ec.europa.eu/repository/handle/J...This JRC technical report gives an overview of a large project on vaccination acceptance and demand and illustrates its outcomes and lessons learnt. The project started at the end of 2019 and was completed in 2022. The overarching objective of the project was to facilitate and execute research on vaccine confidence, identifying behavioural
-
Optimal vaccination strategies
https://publications.jrc.ec.europa.eu/repository/handle/J...Optimal distribution of vaccines to achieve high population immunity levels is a desirable aim in infectious disease epidemiology. A distributed optimal control epidemiological model that accounts for vaccination was developed and applied to the case of the COVID-19 pandemic. The model proposed here is nonstandard and takes into account
-
-
Bluetongue conference on vaccination
https://food.ec.europa.eu/animals/animal-diseases/surveil...Conference held in Brussels - 16 January 2008
-
Vaccination
https://health.ec.europa.eu/vaccination_enVaccination
-
communication-eu-strategy-vaccines-covid19_fr.pdf
https://commission.europa.eu/document/download/3e780eef-7...FR FR COMMISSION EUROPÉENNE Bruxelles, le 17.6.2020 COM(2020) 245 final COMMUNICATION DE LA COMMISSION AU PARLEMENT EUROPÉEN, AU CONSEIL EUROPÉEN, AU CONSEIL ET À LA BANQUE EUROPÉENNE D'INVESTISSEMENT Stratégie de l’Union européenne concernant les vaccins contre la COVID-19 1 1. IL EST URGENT D’AGIR La pandémie de COVID-19 a un coût
-
mobile vaccination caravan and COVID-19 vaccine uptake
https://publications.jrc.ec.europa.eu/repository/handle/J...Over three years since the first COVID-19 vaccine was approved, many countries still have suboptimal vaccination rates despite holding great amounts of vaccines. Overall, there is little evidence on which policies are more effective to encourage vaccination, particularly in countries where a large share of the population remains unvaccinated
-
EU Vaccines Strategy
https://commission.europa.eu/strategy-and-policy/coronavi...The development and deployment of an effective and safe vaccine against the coronavirus represents a permanent solution to the pandemic.
-
Bluetongue conference on vaccination
https://food.ec.europa.eu/animals/animal-diseases/surveil...Conference held in Brussels - 16 January 2008
-
Vaccine-preventable cancers
https://health.ec.europa.eu/vaccination/vaccine-preventab...Cancers caused by Human papillomaviruses (HPV) and Hepatitis B virus (HBV) can be prevented thanks to vaccination.
-
A groundbreaking coronavirus vaccine
https://research-and-innovation.ec.europa.eu/events/speci...Right after the pandemic started, the EU rapidly implemented several measures to respond to COVID-19. One notable action was providing funding and a guarantee through the European Investment Bank (EIB) to help BioNTech in developing a safe and effective vaccine.
-
Improving vaccines
https://publications.jrc.ec.europa.eu/repository/handle/J...Adjuvants have been used for decades to enhance the immune response to vaccines, in particular for the subunit-based ones. Physicochemical properties of the adjuvant-protein antigen complexes, such as size, morphology, protein structure and binding, influence the overall efficacy and safety of the vaccine. Here we show how to perform an accurate
-
Behavioural insights applied to vaccination
https://publications.jrc.ec.europa.eu/repository/handle/J...This JRC technical report gives an overview of a large project on vaccination acceptance and demand and illustrates its outcomes and lessons learnt. The project started at the end of 2019 and was completed in 2022. The overarching objective of the project was to facilitate and execute research on vaccine confidence, identifying behavioural
-
Optimal vaccination strategies
https://publications.jrc.ec.europa.eu/repository/handle/J...Optimal distribution of vaccines to achieve high population immunity levels is a desirable aim in infectious disease epidemiology. A distributed optimal control epidemiological model that accounts for vaccination was developed and applied to the case of the COVID-19 pandemic. The model proposed here is nonstandard and takes into account
-
-
Vaccine-preventable cancers
https://health.ec.europa.eu/vaccination/vaccine-preventab...Cancers caused by Human papillomaviruses (HPV) and Hepatitis B virus (HBV) can be prevented thanks to vaccination.
-
Vaccination
https://health.ec.europa.eu/vaccination_enVaccination
-
communication-eu-strategy-vaccines-covid19_fr.pdf
https://commission.europa.eu/document/download/3e780eef-7...FR FR COMMISSION EUROPÉENNE Bruxelles, le 17.6.2020 COM(2020) 245 final COMMUNICATION DE LA COMMISSION AU PARLEMENT EUROPÉEN, AU CONSEIL EUROPÉEN, AU CONSEIL ET À LA BANQUE EUROPÉENNE D'INVESTISSEMENT Stratégie de l’Union européenne concernant les vaccins contre la COVID-19 1 1. IL EST URGENT D’AGIR La pandémie de COVID-19 a un coût
-
mobile vaccination caravan and COVID-19 vaccine uptake
https://publications.jrc.ec.europa.eu/repository/handle/J...Over three years since the first COVID-19 vaccine was approved, many countries still have suboptimal vaccination rates despite holding great amounts of vaccines. Overall, there is little evidence on which policies are more effective to encourage vaccination, particularly in countries where a large share of the population remains unvaccinated
-
EU Vaccines Strategy
https://commission.europa.eu/strategy-and-policy/coronavi...The development and deployment of an effective and safe vaccine against the coronavirus represents a permanent solution to the pandemic.
-
Bluetongue conference on vaccination
https://food.ec.europa.eu/animals/animal-diseases/surveil...Conference held in Brussels - 16 January 2008
-
Vaccine-preventable cancers
https://health.ec.europa.eu/vaccination/vaccine-preventab...Cancers caused by Human papillomaviruses (HPV) and Hepatitis B virus (HBV) can be prevented thanks to vaccination.
-
A groundbreaking coronavirus vaccine
https://research-and-innovation.ec.europa.eu/events/speci...Right after the pandemic started, the EU rapidly implemented several measures to respond to COVID-19. One notable action was providing funding and a guarantee through the European Investment Bank (EIB) to help BioNTech in developing a safe and effective vaccine.
-
Improving vaccines
https://publications.jrc.ec.europa.eu/repository/handle/J...Adjuvants have been used for decades to enhance the immune response to vaccines, in particular for the subunit-based ones. Physicochemical properties of the adjuvant-protein antigen complexes, such as size, morphology, protein structure and binding, influence the overall efficacy and safety of the vaccine. Here we show how to perform an accurate
-
Behavioural insights applied to vaccination
https://publications.jrc.ec.europa.eu/repository/handle/J...This JRC technical report gives an overview of a large project on vaccination acceptance and demand and illustrates its outcomes and lessons learnt. The project started at the end of 2019 and was completed in 2022. The overarching objective of the project was to facilitate and execute research on vaccine confidence, identifying behavioural
-
Optimal vaccination strategies
https://publications.jrc.ec.europa.eu/repository/handle/J...Optimal distribution of vaccines to achieve high population immunity levels is a desirable aim in infectious disease epidemiology. A distributed optimal control epidemiological model that accounts for vaccination was developed and applied to the case of the COVID-19 pandemic. The model proposed here is nonstandard and takes into account
-
-
A groundbreaking coronavirus vaccine
https://research-and-innovation.ec.europa.eu/events/speci...Right after the pandemic started, the EU rapidly implemented several measures to respond to COVID-19. One notable action was providing funding and a guarantee through the European Investment Bank (EIB) to help BioNTech in developing a safe and effective vaccine.
-
Vaccination
https://health.ec.europa.eu/vaccination_enVaccination
-
communication-eu-strategy-vaccines-covid19_fr.pdf
https://commission.europa.eu/document/download/3e780eef-7...FR FR COMMISSION EUROPÉENNE Bruxelles, le 17.6.2020 COM(2020) 245 final COMMUNICATION DE LA COMMISSION AU PARLEMENT EUROPÉEN, AU CONSEIL EUROPÉEN, AU CONSEIL ET À LA BANQUE EUROPÉENNE D'INVESTISSEMENT Stratégie de l’Union européenne concernant les vaccins contre la COVID-19 1 1. IL EST URGENT D’AGIR La pandémie de COVID-19 a un coût
-
mobile vaccination caravan and COVID-19 vaccine uptake
https://publications.jrc.ec.europa.eu/repository/handle/J...Over three years since the first COVID-19 vaccine was approved, many countries still have suboptimal vaccination rates despite holding great amounts of vaccines. Overall, there is little evidence on which policies are more effective to encourage vaccination, particularly in countries where a large share of the population remains unvaccinated
-
EU Vaccines Strategy
https://commission.europa.eu/strategy-and-policy/coronavi...The development and deployment of an effective and safe vaccine against the coronavirus represents a permanent solution to the pandemic.
-
Bluetongue conference on vaccination
https://food.ec.europa.eu/animals/animal-diseases/surveil...Conference held in Brussels - 16 January 2008
-
Vaccine-preventable cancers
https://health.ec.europa.eu/vaccination/vaccine-preventab...Cancers caused by Human papillomaviruses (HPV) and Hepatitis B virus (HBV) can be prevented thanks to vaccination.
-
A groundbreaking coronavirus vaccine
https://research-and-innovation.ec.europa.eu/events/speci...Right after the pandemic started, the EU rapidly implemented several measures to respond to COVID-19. One notable action was providing funding and a guarantee through the European Investment Bank (EIB) to help BioNTech in developing a safe and effective vaccine.
-
Improving vaccines
https://publications.jrc.ec.europa.eu/repository/handle/J...Adjuvants have been used for decades to enhance the immune response to vaccines, in particular for the subunit-based ones. Physicochemical properties of the adjuvant-protein antigen complexes, such as size, morphology, protein structure and binding, influence the overall efficacy and safety of the vaccine. Here we show how to perform an accurate
-
Behavioural insights applied to vaccination
https://publications.jrc.ec.europa.eu/repository/handle/J...This JRC technical report gives an overview of a large project on vaccination acceptance and demand and illustrates its outcomes and lessons learnt. The project started at the end of 2019 and was completed in 2022. The overarching objective of the project was to facilitate and execute research on vaccine confidence, identifying behavioural
-
Optimal vaccination strategies
https://publications.jrc.ec.europa.eu/repository/handle/J...Optimal distribution of vaccines to achieve high population immunity levels is a desirable aim in infectious disease epidemiology. A distributed optimal control epidemiological model that accounts for vaccination was developed and applied to the case of the COVID-19 pandemic. The model proposed here is nonstandard and takes into account
-
-
Improving vaccines
https://publications.jrc.ec.europa.eu/repository/handle/J...Adjuvants have been used for decades to enhance the immune response to vaccines, in particular for the subunit-based ones. Physicochemical properties of the adjuvant-protein antigen complexes, such as size, morphology, protein structure and binding, influence the overall efficacy and safety of the vaccine. Here we show how to perform an accurate
-
Vaccination
https://health.ec.europa.eu/vaccination_enVaccination
-
communication-eu-strategy-vaccines-covid19_fr.pdf
https://commission.europa.eu/document/download/3e780eef-7...FR FR COMMISSION EUROPÉENNE Bruxelles, le 17.6.2020 COM(2020) 245 final COMMUNICATION DE LA COMMISSION AU PARLEMENT EUROPÉEN, AU CONSEIL EUROPÉEN, AU CONSEIL ET À LA BANQUE EUROPÉENNE D'INVESTISSEMENT Stratégie de l’Union européenne concernant les vaccins contre la COVID-19 1 1. IL EST URGENT D’AGIR La pandémie de COVID-19 a un coût
-
mobile vaccination caravan and COVID-19 vaccine uptake
https://publications.jrc.ec.europa.eu/repository/handle/J...Over three years since the first COVID-19 vaccine was approved, many countries still have suboptimal vaccination rates despite holding great amounts of vaccines. Overall, there is little evidence on which policies are more effective to encourage vaccination, particularly in countries where a large share of the population remains unvaccinated
-
EU Vaccines Strategy
https://commission.europa.eu/strategy-and-policy/coronavi...The development and deployment of an effective and safe vaccine against the coronavirus represents a permanent solution to the pandemic.
-
Bluetongue conference on vaccination
https://food.ec.europa.eu/animals/animal-diseases/surveil...Conference held in Brussels - 16 January 2008
-
Vaccine-preventable cancers
https://health.ec.europa.eu/vaccination/vaccine-preventab...Cancers caused by Human papillomaviruses (HPV) and Hepatitis B virus (HBV) can be prevented thanks to vaccination.
-
A groundbreaking coronavirus vaccine
https://research-and-innovation.ec.europa.eu/events/speci...Right after the pandemic started, the EU rapidly implemented several measures to respond to COVID-19. One notable action was providing funding and a guarantee through the European Investment Bank (EIB) to help BioNTech in developing a safe and effective vaccine.
-
Improving vaccines
https://publications.jrc.ec.europa.eu/repository/handle/J...Adjuvants have been used for decades to enhance the immune response to vaccines, in particular for the subunit-based ones. Physicochemical properties of the adjuvant-protein antigen complexes, such as size, morphology, protein structure and binding, influence the overall efficacy and safety of the vaccine. Here we show how to perform an accurate
-
Behavioural insights applied to vaccination
https://publications.jrc.ec.europa.eu/repository/handle/J...This JRC technical report gives an overview of a large project on vaccination acceptance and demand and illustrates its outcomes and lessons learnt. The project started at the end of 2019 and was completed in 2022. The overarching objective of the project was to facilitate and execute research on vaccine confidence, identifying behavioural
-
Optimal vaccination strategies
https://publications.jrc.ec.europa.eu/repository/handle/J...Optimal distribution of vaccines to achieve high population immunity levels is a desirable aim in infectious disease epidemiology. A distributed optimal control epidemiological model that accounts for vaccination was developed and applied to the case of the COVID-19 pandemic. The model proposed here is nonstandard and takes into account
-
-
Behavioural insights applied to vaccination
https://publications.jrc.ec.europa.eu/repository/handle/J...This JRC technical report gives an overview of a large project on vaccination acceptance and demand and illustrates its outcomes and lessons learnt. The project started at the end of 2019 and was completed in 2022. The overarching objective of the project was to facilitate and execute research on vaccine confidence, identifying behavioural
-
Vaccination
https://health.ec.europa.eu/vaccination_enVaccination
-
communication-eu-strategy-vaccines-covid19_fr.pdf
https://commission.europa.eu/document/download/3e780eef-7...FR FR COMMISSION EUROPÉENNE Bruxelles, le 17.6.2020 COM(2020) 245 final COMMUNICATION DE LA COMMISSION AU PARLEMENT EUROPÉEN, AU CONSEIL EUROPÉEN, AU CONSEIL ET À LA BANQUE EUROPÉENNE D'INVESTISSEMENT Stratégie de l’Union européenne concernant les vaccins contre la COVID-19 1 1. IL EST URGENT D’AGIR La pandémie de COVID-19 a un coût
-
mobile vaccination caravan and COVID-19 vaccine uptake
https://publications.jrc.ec.europa.eu/repository/handle/J...Over three years since the first COVID-19 vaccine was approved, many countries still have suboptimal vaccination rates despite holding great amounts of vaccines. Overall, there is little evidence on which policies are more effective to encourage vaccination, particularly in countries where a large share of the population remains unvaccinated
-
EU Vaccines Strategy
https://commission.europa.eu/strategy-and-policy/coronavi...The development and deployment of an effective and safe vaccine against the coronavirus represents a permanent solution to the pandemic.
-
Bluetongue conference on vaccination
https://food.ec.europa.eu/animals/animal-diseases/surveil...Conference held in Brussels - 16 January 2008
-
Vaccine-preventable cancers
https://health.ec.europa.eu/vaccination/vaccine-preventab...Cancers caused by Human papillomaviruses (HPV) and Hepatitis B virus (HBV) can be prevented thanks to vaccination.
-
A groundbreaking coronavirus vaccine
https://research-and-innovation.ec.europa.eu/events/speci...Right after the pandemic started, the EU rapidly implemented several measures to respond to COVID-19. One notable action was providing funding and a guarantee through the European Investment Bank (EIB) to help BioNTech in developing a safe and effective vaccine.
-
Improving vaccines
https://publications.jrc.ec.europa.eu/repository/handle/J...Adjuvants have been used for decades to enhance the immune response to vaccines, in particular for the subunit-based ones. Physicochemical properties of the adjuvant-protein antigen complexes, such as size, morphology, protein structure and binding, influence the overall efficacy and safety of the vaccine. Here we show how to perform an accurate
-
Behavioural insights applied to vaccination
https://publications.jrc.ec.europa.eu/repository/handle/J...This JRC technical report gives an overview of a large project on vaccination acceptance and demand and illustrates its outcomes and lessons learnt. The project started at the end of 2019 and was completed in 2022. The overarching objective of the project was to facilitate and execute research on vaccine confidence, identifying behavioural
-
Optimal vaccination strategies
https://publications.jrc.ec.europa.eu/repository/handle/J...Optimal distribution of vaccines to achieve high population immunity levels is a desirable aim in infectious disease epidemiology. A distributed optimal control epidemiological model that accounts for vaccination was developed and applied to the case of the COVID-19 pandemic. The model proposed here is nonstandard and takes into account
-
-
Optimal vaccination strategies
https://publications.jrc.ec.europa.eu/repository/handle/J...Optimal distribution of vaccines to achieve high population immunity levels is a desirable aim in infectious disease epidemiology. A distributed optimal control epidemiological model that accounts for vaccination was developed and applied to the case of the COVID-19 pandemic. The model proposed here is nonstandard and takes into account
-
Vaccination
https://health.ec.europa.eu/vaccination_enVaccination
-
communication-eu-strategy-vaccines-covid19_fr.pdf
https://commission.europa.eu/document/download/3e780eef-7...FR FR COMMISSION EUROPÉENNE Bruxelles, le 17.6.2020 COM(2020) 245 final COMMUNICATION DE LA COMMISSION AU PARLEMENT EUROPÉEN, AU CONSEIL EUROPÉEN, AU CONSEIL ET À LA BANQUE EUROPÉENNE D'INVESTISSEMENT Stratégie de l’Union européenne concernant les vaccins contre la COVID-19 1 1. IL EST URGENT D’AGIR La pandémie de COVID-19 a un coût
-
mobile vaccination caravan and COVID-19 vaccine uptake
https://publications.jrc.ec.europa.eu/repository/handle/J...Over three years since the first COVID-19 vaccine was approved, many countries still have suboptimal vaccination rates despite holding great amounts of vaccines. Overall, there is little evidence on which policies are more effective to encourage vaccination, particularly in countries where a large share of the population remains unvaccinated
-
EU Vaccines Strategy
https://commission.europa.eu/strategy-and-policy/coronavi...The development and deployment of an effective and safe vaccine against the coronavirus represents a permanent solution to the pandemic.
-
Bluetongue conference on vaccination
https://food.ec.europa.eu/animals/animal-diseases/surveil...Conference held in Brussels - 16 January 2008
-
Vaccine-preventable cancers
https://health.ec.europa.eu/vaccination/vaccine-preventab...Cancers caused by Human papillomaviruses (HPV) and Hepatitis B virus (HBV) can be prevented thanks to vaccination.
-
A groundbreaking coronavirus vaccine
https://research-and-innovation.ec.europa.eu/events/speci...Right after the pandemic started, the EU rapidly implemented several measures to respond to COVID-19. One notable action was providing funding and a guarantee through the European Investment Bank (EIB) to help BioNTech in developing a safe and effective vaccine.
-
Improving vaccines
https://publications.jrc.ec.europa.eu/repository/handle/J...Adjuvants have been used for decades to enhance the immune response to vaccines, in particular for the subunit-based ones. Physicochemical properties of the adjuvant-protein antigen complexes, such as size, morphology, protein structure and binding, influence the overall efficacy and safety of the vaccine. Here we show how to perform an accurate
-
Behavioural insights applied to vaccination
https://publications.jrc.ec.europa.eu/repository/handle/J...This JRC technical report gives an overview of a large project on vaccination acceptance and demand and illustrates its outcomes and lessons learnt. The project started at the end of 2019 and was completed in 2022. The overarching objective of the project was to facilitate and execute research on vaccine confidence, identifying behavioural
-
Optimal vaccination strategies
https://publications.jrc.ec.europa.eu/repository/handle/J...Optimal distribution of vaccines to achieve high population immunity levels is a desirable aim in infectious disease epidemiology. A distributed optimal control epidemiological model that accounts for vaccination was developed and applied to the case of the COVID-19 pandemic. The model proposed here is nonstandard and takes into account
-